Myeloid derived suppressor cells in human diseases.
Myeloid derived suppressor cells (MDSC) have been described as a heterogeneous cell population with potent immune suppressor function in mice. Limited data are available on MDSC in human diseases. Interpretation of these data is complicated by the fact that different markers have been used to analyze human MDSC subtypes in various clinical settings. Human MDSC are CD11b+, CD33+, HLA-DR(neg/low) and can be divided into granulocytic CD14⁻ and monocytic CD14+ subtypes. Interleukin 4Rα, VEGFR, CD15 and CD66b have been suggested to be more specific markers for human MDSC, however these markers can only be found on some MDSC subsets. Until today the best marker for human MDSC remains their suppressor function, which can be either direct or indirect through the induction of regulatory T cells. Immune suppressor activity has been associated with high arginase 1 and iNOS activity as well as ROS production by MDSC. Not only in murine models, but even more importantly in patients with cancer, different drugs have been shown to either reverse the immune suppressor function of MDSC or directly target these cells. Systemic treatment with all-trans-retinoic acid has been shown to mature human MDSC and reverse their immune suppressor function. Alternatively, MDSC can be targeted by treatment with the multi-targeted receptor tyrosine kinase inhibitor sunitinib. This review will provide a comprehensive summary of the recent literature on human MDSC.
National Institutes of Health, National Cancer Institute, Medical Oncology Branch, 9000 Rockville Pike, Bethesda MD 20892, USA. tim.greten@nih.gov
Tim F
TF
Greten
Michael P
MP
Manns
Firouzeh
F
Korangy
D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D006801:Humans; D007165:Immunosuppression Therapy; D007211:Indoles / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000276:immunology* / Q000473:pathology; D051379:Mice; D058990:Molecular Targeted Therapy; D022423:Myeloid Cells / Q000187:drug effects / Q000276:immunology*; D038042:Myelopoiesis / Q000187:drug effects; D009369:Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D011758:Pyrroles / Q000627:therapeutic use; D000077210:Sunitinib; D014212:Tretinoin / Q000627:therapeutic use
D015415:Biomarkers; D007211:Indoles; D011758:Pyrroles; D014212:Tretinoin; D000077210:Sunitinib
Cancer Immunol Immunother. 2008 Oct;57(10):1493-504
18322683
J Immunol. 2008 Jul 1;181(1):346-53
18566400
Eur J Immunol. 2009 Oct;39(10):2865-76
19637228
J Immunol. 2008 Jun 15;180(12):7898-906
18523253
Clin Cancer Res. 2008 Sep 15;14(18):5884-92
18794101
Cancer Immunol Immunother. 2010 Oct;59(10):1593-600
20414655
Blood. 2008 Nov 15;112(10):4080-9
18753637
Cancer Res. 2010 Jun 1;70(11):4335-45
20484028
J Immunother. 2009 Jan;32(1):1-11
19307988
Blood. 2010 Dec 16;116(25):5738-47
20807889
J Immunol. 2010 Nov 15;185(10):5828-34
20956337
Clin Cancer Res. 2007 Aug 15;13(16):4840-8
17699863
Clin Cancer Res. 2008 Dec 15;14(24):8270-8
19088044
Stem Cells. 2010 Mar 31;28(3):620-32
20073041
J Exp Med. 2007 Jun 11;204(6):1463-74
17548519
J Leukoc Biol. 2011 Feb;89(2):311-7
21106641
Cancer Res. 2007 May 1;67(9):4507-13
17483367
J Exp Med. 2006 Nov 27;203(12):2691-702
17101732
Prostate. 2010 Mar 1;70(4):443-55
19902470
Cancer Res. 1987 Jan 1;47(1):100-5
2947676
Nat Med. 2007 Jul;13(7):828-35
17603493
Immunity. 2010 Jun 25;32(6):790-802
20605485
Immunology. 2009 Sep;128(1):141-9
19689743
J Immunol. 2009 May 15;182(10):6562-8
19414811
J Immunol. 2010 Aug 15;185(4):2273-84
20644162
Cancer Res. 2001 Jun 15;61(12):4756-60
11406548
Nat Rev Immunol. 2009 Mar;9(3):162-74
19197294
Clin Cancer Res. 2005 Sep 15;11(18):6713-21
16166452
Cancer Immunol Immunother. 2004 Jun;53(6):551-9
14727087
World J Gastroenterol. 2006 May 28;12(20):3275-82
16718852
Blood. 2007 May 15;109(10):4336-42
17244679
Clin Cancer Res. 2009 Mar 15;15(6):2148-57
19276286
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
18446337
Cancer Immunol Immunother. 2004 May;53(5):422-30
14648070
J Exp Med. 2010 Oct 25;207(11):2439-53
20876310
Eur J Immunol. 2010 Nov;40(11):2969-75
21061430
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90
15753302
J Immunol. 2001 May 1;166(9):5398-406
11313376
J Clin Oncol. 2007 Jun 20;25(18):2546-53
17577033
J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45
19572148
J Clin Invest. 2008 Dec;118(12):4036-48
19033672
J Immunol. 2009 May 1;182(9):5693-701
19380816
J Immunol. 2007 Oct 15;179(8):5228-37
17911608
Cancer Res. 2006 Sep 15;66(18):9299-307
16982775
Blood. 2007 Feb 15;109(4):1568-73
17023580
Cancer Res. 2010 Apr 15;70(8):3052-61
20388795
Cancer Res. 2007 Nov 15;67(22):11021-8
18006848
J Immunol. 1998 Nov 15;161(10):5313-20
9820504
Cancer Res. 2009 Mar 15;69(6):2506-13
19244102
Cancer Res. 2005 Apr 15;65(8):3044-8
15833831
Mol Med. 2011 Mar-Apr;17(3-4):281-92
21085745
Clin Cancer Res. 1995 Jan;1(1):95-103
9815891
Cancer Res. 2009 Feb 15;69(4):1553-60
19201693
Clin Cancer Res. 2010 Mar 15;16(6):1812-23
20215551
J Immunol. 2009 Feb 15;182(4):1818-28
19201833
Scand J Immunol. 2010 Dec;72(6):540-7
21044128
Hepatology. 2009 Sep;50(3):799-807
19551844
Eur J Immunol. 2010 Nov;40(11):2976-85
21061431
J Clin Invest. 2006 Oct;116(10):2777-90
17016559
J Exp Med. 2005 Oct 3;202(7):931-9
16186186
J Immunol. 2001 Jan 1;166(1):678-89
11123353
J Immunother. 2000 Jan;23(1):115-24
10687144
J Immunol. 2009 Dec 1;183(11):6971-80
19890055
Cancer Res. 2006 Sep 15;66(18):9290-8
16982774
Gastroenterology. 2008 Sep;135(3):871-81, 881.e1-5
18674538
Cancer Res. 2008 Jul 1;68(13):5439-49
18593947
Gastroenterology. 2008 Jul;135(1):234-43
18485901
J Clin Oncol. 2008 Jul 1;26(19):3235-41
18591558
J Immunol. 2009 Jan 1;182(1):240-9
19109155
Cancer Res. 2007 Dec 1;67(23):11438-46
18056472